Perimeter Medical Imaging AI, Inc.

Perimeter Medical Imaging AI, Inc. is a medical technology firm focused on developing and marketing advanced imaging solutions. These innovations empower surgeons, radiologists, and pathologists to meticulously examine microscopic tissue structures directly within a clinical setting. A cornerstone offering is their optical coherence tomography (OCT) imaging system, which delivers detailed cross-sectional views of tissues to a depth of 2 millimeters, comprising the S-series OCT, B-series OCT, and an associated imaging console. Complementing this, ImgAssist, an artificial intelligence platform, streamlines image analysis. When integrated with Perimeter's OCT technology, ImgAssist becomes a robust tool, providing physicians with real-time visualization and assessment of surgical margins. This capability significantly enhances patient surgical outcomes and diminishes the necessity for subsequent operations. The company further provides a specialized image library and disposable specimen containers, catering to hospitals and cancer treatment facilities. Established in 2013, Perimeter Medical Imaging AI, Inc. operates from its headquarters in Toronto, Canada.

Perimeter Medical Imaging AI, Inc. trades as PINK.V on TSXV. The company is classified in Healthcare / Medical - Devices and reports in CAD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $2.34M of revenue and -$13.14M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Perimeter Medical Imaging AI, Inc. can be compared against peers such as Aurora Spine Corporation, BriaCell Therapeutics Corp., Charlotte's Web Holdings, Inc., Gemina Laboratories Ltd., Izotropic Corporation, MediPharm Labs Corp..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $27.42M, beta of 1.08, and return on equity of -319.0%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PINK.V currently shows total debt of $119,105 and beta of 1.08. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.perimetermed.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.